Reply to the article “oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases” by J.-J. Body et al.

Yaman E, Benekli M, Coskun U, Ozturk B, Kaya AO, Yildiz R, Buyukberber S.

Reply to the article “oral ibandronate is as active as intravenous zoledronic acid for reducing bone turnover markers in women with breast cancer and bone metastases” by J.-J. Body et al. (Ann Oncol 2007; 18: 1165-1171). Ann Oncol.

2008 Feb;19(2):397-8; author reply 398. PubMed PMID: 18260185.